Following the termination of the pact, Anapharm Europe’s majority shareholder Maria Cruz Caturla has acquired PharmaNet’s minority ownership interest, and now he is the sole owner of the drug development services provider, PharmaNet.
The companies will independently continue to invest in, and provide to clients, bioanalytical services in their respective laboratory facilities.
Additionally, to the extent necessary, PharmaNet Development Group and Anapharm Europe will provide coordinated support for those client projects undertaken jointly during the term of the joint venture.